Annexon/$ANNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Ticker
$ANNX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
106
ISIN
US03589W1027
Website
Annexon Metrics
BasicAdvanced
$307M
-
-$1.16
1.24
-
Price and volume
Market cap
$307M
Beta
1.24
52-week high
$7.55
52-week low
$1.29
Average daily volume
1.8M
Financial strength
Current ratio
7.994
Quick ratio
7.86
Long term debt to equity
10.539
Total debt to equity
11.612
Profitability
EBITDA (TTM)
-180.757
Management effectiveness
Return on assets (TTM)
-37.66%
Return on equity (TTM)
-66.13%
Valuation
Price to book
1.26
Price to tangible book (TTM)
1.26
Price to free cash flow (TTM)
-2.878
Free cash flow yield (TTM)
-34.75%
Free cash flow per share (TTM)
-97.30%
Growth
Earnings per share change (TTM)
-15.26%
3-year earnings per share growth (CAGR)
-31.58%
What the Analysts think about Annexon
Analyst ratings (Buy, Hold, Sell) for Annexon stock.
Bulls say / Bears say
Annexon's lead candidate, ANX005, demonstrated significant efficacy in a Phase 3 trial for Guillain-Barré Syndrome, showing a 2.4-fold higher likelihood of improved health at Week 8 compared to placebo. (stocktitan.net)
Analysts have assigned a consensus 'Buy' rating to Annexon, with an average 12-month price target of $15.80, indicating strong confidence in the company's growth potential. (americanbankingnews.com)
Director William H. Carson increased his stake in Annexon by purchasing 3,200 shares, signaling insider confidence in the company's future prospects. (investing.com)
Annexon's stock has declined by 53.4% year-to-date, reflecting investor concerns over the company's financial performance. (marketbeat.com)
The company reported a net loss of $167.38 million over the trailing twelve months, raising questions about its path to profitability. (stockanalysis.com)
Annexon's stock price is currently 78.60% below its 52-week high, indicating significant market volatility and potential investor skepticism. (investchronicle.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Annexon Financial Performance
Revenues and expenses
Annexon Earnings Performance
Company profitability
Annexon News
AllArticlesVideos
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
GlobeNewsWire·3 weeks ago
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Annexon stock?
Annexon (ANNX) has a market cap of $307M as of July 11, 2025.
What is the P/E ratio for Annexon stock?
The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of July 11, 2025.
Does Annexon stock pay dividends?
No, Annexon (ANNX) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Annexon dividend payment date?
Annexon (ANNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Annexon?
Annexon (ANNX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.